New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, ...

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity ...

Participants who received tirzepatide, the active ingredient in Zepbound, also had greater reductions in waist size and more significant improvements in metabolic risk factors. Tirzepatide’s dual ...

Discover a study comparing tirzepatide, semaglutide, and liraglutide in MASLD, revealing significant reductions in liver ...

SaveHealth reports that Zepbound and Wegovy, both FDA-approved weight loss injectables, differ in mechanisms and efficacy.

Mounjaro, originally developed as a diabetes drug, has skyrocketed to become India’s no. 2 pharma brand, thanks to a booming ...

New guidance from the European Association for the Study of Obesity says that semaglutide or tirzepatide should be first-line drugs for obesity and most related complications.

Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment ...

Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials, in a further sign of the insatiable investor appetite for ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...